PPIDT00028

Drug Information
NameInsulin human
SequenceGIVEQCCTSICSLYQLENYCN
DrugBank_IDDB00030
Typebiotech
IndicationHuman insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Dosage Forms
Form Route Strength
Injection, suspension Cutaneous; Parenteral
100 IU/ml
Injection, suspension Cutaneous; Parenteral
40 IU/ml
Injection, suspension Parenteral; Subcutaneous
100 UI/ML
Injection, suspension Parenteral; Subcutaneous
100 IU/ml
Injection, suspension Parenteral; Subcutaneous
40 UI/ML
Injection, suspension Parenteral
Injection, solution Intravenous; Parenteral
100 IU/ML
Injection, solution Intravenous; Parenteral
40 IU/ML
Injection, solution Intravenous; Subcutaneous
100 IU/ML
Injection, solution Intravenous; Subcutaneous
40 iu/ml
Injection, solution Parenteral; Subcutaneous
100 IU/ML
Solution Subcutaneous
Injection, solution Parenteral
100 IU/mL
Injection —
Injection Intramuscular; Intravenous; Subcutaneous
100 IU/ml
Injection, solution Parenteral
100 IE
Injection, solution Parenteral
100 IE/ML
Injection, solution Parenteral
100 I.E./ML
Solution Subcutaneous
100 IU/ml
Solution —
100 IU/ml
Kit Respiratory (inhalation)
Powder, metered Respiratory (inhalation)
12 [arb'U]/1
Powder, metered Respiratory (inhalation)
4 [arb'U]/1
Powder, metered Respiratory (inhalation)
5
Powder, metered Respiratory (inhalation)
8 [arb'U]/1
Powder, metered Respiratory (inhalation)
9
Injection, suspension Parenteral
3 ML
Injection, solution Parenteral
3 ML
Injection, suspension Subcutaneous
Injection, suspension —
100 iu/1ml
Solution Subcutaneous
500 unit / mL
Aerosol, powder Respiratory (inhalation)
1 mg/1
Aerosol, powder Respiratory (inhalation)
3 mg/1
Powder Oral
1 mg
Solution Parenteral
100.00 UI
Injection Parenteral
Injection, solution Subcutaneous
Injection, solution —
Injection, suspension Parenteral
100 IU
Injection, suspension Parenteral
1000 IU
Injection, solution Parenteral
100 IU
Injection, solution Intravenous
100 IU/ML
Injection, solution Subcutaneous
100 IU/ML
Injection, suspension Subcutaneous
100 units/mL
Injection, suspension Subcutaneous
40 units/mL
Suspension Subcutaneous
Injection Subcutaneous
100 U/ML
Injection Intramuscular; Subcutaneous
Injection, suspension —
100 IU
Injection, suspension Subcutaneous
100 [iU]/1mL
Injection, suspension Subcutaneous
100
Injection, suspension Parenteral
300 IU
Injection Subcutaneous
Suspension Subcutaneous
100 unit/mL
Suspension Subcutaneous
100 unit / mL
Injection Intramuscular; Subcutaneous
100 iu/ml
Injection, solution Parenteral
300 IU
Injection, solution —
100 IU
Injection, solution Parenteral
100 [iU]/1mL
Injection, solution Subcutaneous
100 [iU]/1mL
Solution Intramuscular; Intravenous; Subcutaneous
100 unit/mL
Solution Subcutaneous
100 UI
Solution Intramuscular; Subcutaneous
100 unit/mL
Injection, solution Subcutaneous
500 [iU]/1mL
Injection, solution Intravenous
1 IU/ml
Injection, solution Intravenous
1 UI/mL
Solution —
100 UI
Injection, suspension Subcutaneous
100 IU/mL
Suspension Subcutaneous
Injection —
100 iu/ml
Injection, suspension Parenteral
100 IE/ML
Injection Subcutaneous
100 IU/ml
Injection, suspension Subcutaneous
30 iu/1mL
Suspension Intramuscular; Subcutaneous
10000000 IU
Solution Subcutaneous
10000000 IU
Solution Parenteral
100.000 UI
Injection, solution Intramuscular; Parenteral
100 IU/ML
Injection, solution Intravenous; Parenteral
100 UI/ML
Injection, solution Parenteral; Subcutaneous
100 UI/ML
Injection, solution Parenteral; Subcutaneous
40 UI/ML
Injection, suspension Intramuscular
100 IU/ml
Injection, suspension Intramuscular
40 IU/ml
Injection, suspension Intramuscular; Subcutaneous
100 IU/ml
Injection, suspension Subcutaneous
100 UI/ML
Injection, suspension Subcutaneous
40 UI/ML
Injection, suspension Subcutaneous
40 IU/ml
Solution Subcutaneous
100 UI/ML
Solution Subcutaneous
40 UI/ML
Suspension —
100 IU/ML
Injection, suspension Parenteral
100 I.E./ML
Injection, suspension Parenteral
40 IE/ML
Injection, suspension Parenteral
100 IE
Suspension Subcutaneous
100 IU/ml
Injection, solution Intraperitoneal
400 IU/ml
Injection, solution Parenteral
40 IE/ML
Injection, solution —
100 iu/ml
Injection; injection, solution —
100 IU/ml
Injection —
300 IU/ml
— Subcutaneous
100 unit / mL
Injection Subcutaneous
Injection Subcutaneous
70 IU/ml
Injection, suspension Parenteral
100 IU/ml
Injection, suspension Subcutaneous
Injection, solution Intravenous
1.00 [iU]/1mL
Solution Intravenous
1 unit / mL
Injection, suspension Subcutaneous
100 [USP'U]/1mL
Suspension Subcutaneous
100 UI
Solution Intramuscular; Intravenous; Subcutaneous
100 unit / mL
Solution Other
100 UI
Solution Intravenous; Subcutaneous
10000000 IU
Liquid Intramuscular; Intravenous; Subcutaneous
100 unit / mL
Injection, suspension Parenteral; Subcutaneous
40 IU/ML
Injection, suspension Parenteral
100 UI/ml
Injection —
100 IU
Suspension —
Solution Intramuscular; Intravenous; Subcutaneous
10000000 IU
Suspension Subcutaneous
10000000 IU
Solution Parenteral
100 UI
Suspension Parenteral
100 UI
Injection, suspension —
Suspension —
Suspension —
100 iu/1ml
Injection, solution —
100 iu/1ml
Solution —
100 iu/1ml
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P06213 INSR Insulin receptor Homo sapiens agonist Link
target P08069 IGF1R Insulin-like growth factor 1 receptor Homo sapiens activator Link
target P16870 CPE Carboxypeptidase E Homo sapiens modulator|product of Link
target P48745 CCN3 CCN family member 3 Homo sapiens downregulator Link
target P98164 LRP2 Low-density lipoprotein receptor-related protein 2 Homo sapiens substrate Link
target Q16270 IGFBP7 Insulin-like growth factor-binding protein 7 Homo sapiens inhibitor|binder Link
enzyme P14735 IDE Insulin-degrading enzyme Homo sapiens substrate|cleavage Link
enzyme P16519 PCSK2 Neuroendocrine convertase 2 Homo sapiens activator Link
enzyme P29120 PCSK1 Neuroendocrine convertase 1 Homo sapiens activator Link
enzyme P05177 CYP1A2 Cytochrome P450 1A2 Homo sapiens inducer Link